Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCAR02
- Development stage
- Phase 1
- Lead developer
- 湖南思为康医药
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**SCAR02** is an investigational fourth-generation autologous dual-target CAR-T cell therapy engineered to recognize CD19 and B-cell maturation antigen and to secrete anti-interleukin-6 antibodies. It is intended to deplete pathogenic CD19-positive B-cell and BCMA-expressing plasmablast or plasma-cell populations in refractory autoimmune disease, while IL-6 antibody secretion is intended to mitigate cytokine-release syndrome. SCAR02 has been studied in an open-label, single-site, dose-escalation clinical study for refractory autoimmune diseases and has published preliminary clinical data in refractory systemic lupus erythematosus. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/42297600/))
- Other names
- Anti-BCMA and CD19 CAR-T cells
02
Targets
BCMA (B-cell maturation antigen)CD19 (B lymphocyte antigen CD19)
Beyond the preview
Go deeper on SCAR02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCAR02.